ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
2.630
+0.040 (1.54%)
Dec 20, 2024, 4:00 PM EST - Market closed
ProQR Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for ProQR Therapeutics stock have an average target of 7.60, with a low estimate of 2.00 and a high estimate of 14. The average target predicts an increase of 188.97% from the current stock price of 2.63.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for PRQR stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 0 | 0 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $8 | Buy | Reiterates | $8 | +204.18% | Dec 12, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +52.09% | Dec 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +280.23% | Dec 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $10 | Strong Buy | Maintains | $5 → $10 | +280.23% | Nov 8, 2024 |
| Raymond James | Raymond James | Buy → Strong Buy Upgrades $6 → $14 | Buy → Strong Buy | Upgrades | $6 → $14 | +432.32% | Oct 29, 2024 |
Financial Forecast
Revenue This Year
22.10M
from 6.59M
Increased by 235.11%
Revenue Next Year
20.10M
from 22.10M
Decreased by -9.06%
EPS This Year
-0.31
from -0.35
EPS Next Year
-0.42
from -0.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 30.5M | 45.2M | 20.0M | |||
| Avg | 22.1M | 20.1M | 17.3M | |||
| Low | 14.9M | n/a | 14.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 361.8% | 104.3% | -0.7% | |||
| Avg | 235.1% | -9.1% | -13.7% | |||
| Low | 125.6% | - | -26.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.21 | -0.17 | -0.38 |
| Avg | -0.31 | -0.42 | -0.53 |
| Low | -0.36 | -0.59 | -0.67 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.